NewLink Genetics Corporation (NASDAQ:NLNK) shares fell 6.5% during trading on Tuesday . The company traded as low as $8.45 and last traded at $8.58. 1,506,309 shares traded hands during trading, an increase of 15% from the average session volume of 1,304,436 shares. The stock had previously closed at $9.18.

A number of brokerages have recently commented on NLNK. Stifel Nicolaus increased their price objective on NewLink Genetics Corporation from $14.00 to $29.00 and gave the company a “buy” rating in a report on Monday, September 11th. Cantor Fitzgerald reissued a “buy” rating and set a $26.00 price objective on shares of NewLink Genetics Corporation in a report on Friday, September 8th. ValuEngine lowered NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. Jefferies Group LLC raised NewLink Genetics Corporation from a “hold” rating to a “buy” rating and increased their price objective for the company from $7.00 to $26.00 in a report on Friday, September 8th. Finally, Robert W. Baird raised NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $8.00 to $22.00 in a report on Friday, September 8th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $23.43.

In other NewLink Genetics Corporation news, major shareholder Stine Seed Farm, Inc. bought 780,487 shares of the stock in a transaction on Friday, October 6th. The shares were purchased at an average price of $10.25 per share, with a total value of $7,999,991.75. Following the acquisition, the insider now directly owns 7,857,732 shares of the company’s stock, valued at approximately $80,541,753. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 13.70% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. GSA Capital Partners LLP grew its holdings in NewLink Genetics Corporation by 653.7% in the 3rd quarter. GSA Capital Partners LLP now owns 132,154 shares of the biotechnology company’s stock valued at $1,345,000 after buying an additional 114,620 shares during the last quarter. Neuberger Berman Group LLC acquired a new stake in NewLink Genetics Corporation in the 3rd quarter valued at approximately $305,000. Point72 Asset Management L.P. acquired a new stake in NewLink Genetics Corporation in the 3rd quarter valued at approximately $1,819,000. Perceptive Advisors LLC acquired a new stake in NewLink Genetics Corporation in the 3rd quarter valued at approximately $4,581,000. Finally, Stifel Financial Corp acquired a new stake in NewLink Genetics Corporation in the 3rd quarter valued at approximately $402,000. 46.09% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/22/newlink-genetics-corporation-nlnk-shares-down-6-5.html.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Receive News & Stock Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related stocks with our FREE daily email newsletter.